touchMEETING HIGHLIGHTS ADVENT at EADV 2023: Expert insights on AD in children, PN, and CSU
Watch highlights of three ADVENT symposia presented at EADV 2023
Dr Weidinger outlines how skin barrier dysfunction increases exposure to allergens, increasing the risk of potential sensitization. He then goes on to explain how AD can follow multiple trajectories from childhood through to adulthood.
Dr Simpson explains how type 2 inflammation contributes to skin signs and symptoms in both AD and chronic spontaneous urticaria (CSU); in PN, type 2 inflammation contributes to structural changes and clinical features.
Dr Elmariah outlines how PN may be misdiagnosed as a psychodermatological disorder.
Overview & Learning Objectives
Overview
ADVENT brought global experts together to discuss the latest advances in atopic dermatitis in children and the shared and unique drivers of atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.
Discover more and watch the full symposia at www.adventprogram.com.
Learning Objectives
After watching this activity, participants should be better able to:
- Explain how skin barrier dysfunction in atopic dermatitis (AD) increases the risk of allergen sensitization.
- Describe how type 2 inflammation contributes to the clinical presentation of atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU).
- Understand that PN may be misdiagnosed as a psychodermatological disorder.
Faculty & Disclosures
Dr Stephan Weidinger
University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Dr Stephan Weidinger discloses:
Speaker, advisory board member and/or investigator for: AbbVie, Almirall, Boehringer Ingelheim, Galderma, Kymab, Incyte, Janssen, La Roche-Posay, Leo Pharma, Lilly, Novartis, Pfizer, Regeneron, and Sanofi.
Dr Eric Simpson
Oregon Health and Science University School of Medicine, Portland, OR, USA.
Dr Eric Simpson discloses:
Research funding from: AbbVie, Arcotech Biopharma Inc, Amgen, Arcutis, Aslan, Cattle Biosciences, CorEvitas, Dermavant, Dermira, Eli Lilly, Incyte, Kymab, Kyowa Kirin, National Jewish Health, Leo Pharma, Pfizer, Regeneron, Sanofi, and Target RWE. Speaker and/or consulting fees from: Advances in Cosmetic Medical Derm Hawaii LLC, AbbVie, Amgen, AOBiome LLC, Arcutis Biotherapeutics, Arena Pharmaceuticals, Asian Phama, Boehringer Ingelheim USA Inc, Boston Consulting Group, Bristol Myers Squibb – BMS, Collective Acumen LLC (CA), CorEvitas, Dermira, Eli Lilly, Evelo Biosciences, Evidera, ExcerptaMedica, FIDE, Forte Bio RX, Galderma, GlaxoSmithKline, Gilead Sciences Inc, Incyte, Innovaderm Reche, Janssen, Johnson & Johnson, Kyowa Kirin, Leo Pharma, Medscape LLC, Merck, MauiDerm, MLG, MJH Holding, Pfizer, Physicians World LLC, PRImE, Recluddix Pharma, Regeneron, Revolutionizing Atopic Dermatitis Inc, Roivant, Sanofi-Genzyme, Trevi Therapeutics, Valeant, Vindico Medical Education, and WebMD.
Dr Sarina Elmariah
University of California, San Francisco, CA, USA.
Dr Sarina Elmariah discloses:
Speaker, advisory board member and/or investigator for: BELLUS Health, Galderma, Incyte, Menlo Therapeutics, New Frontier Bio, RAPT Ther, Regeneron, Resolute Bio, Sanofi, and Trevi Therapeutics.
